Eli Lilly and Company and AstraZeneca, who previously partnered to study an investigational treatment for Alzheimer’s disease, have announced the enrollment of the first patient in the study, called AMARANTH[/u]. The Phase II/III study aims to evaluate the safety and efficacy of oral beta secretase cleaving enzyme (BACE) inhibitor, AZD3293